BioWorld - Sunday, July 5, 2026

Analysis and data insight
Analysis and data insight RSS Feed RSS

Capsules and tablets scattered over a world map

MFN drug pricing getting a foothold in the US

Oct. 17, 2025
By Mari Serebrov
No Comments
Caught between the rock and the hard place of most-favored nation (MFN) pricing and the threat of a hefty biopharma sector tariff, drug companies marketing in the U.S. are exploring their options. Several large firms already have committed millions and billions of dollars in investment in new or expanded U.S.-based manufacturing facilities to avoid tariffs on finished drugs.
Read More
Pen and paper

White House ushering in new era of EO governance?

Oct. 15, 2025
By Mari Serebrov
No Comments
While the pace of executive orders (EOs) coming out of the White House has slowed, the Trump administration is still churning them out. As of the end of the third quarter, President Donald Trump had issued 209 EOs. Of those, BioWorld tracked 37 that directly impact drug and device R&D, regulatory burdens, pricing and market competition.
Read More
Biopharma deals September 2025

M&As slow as biopharma dealmaking value jumps 32% in September 2025

Oct. 14, 2025
By Amanda Lanier
No Comments
Biopharma dealmaking was up 32% month over month in September, reaching $27.15 billion in total value, up from $20.52 billion in August. It was the fourth-highest month for deals of the year, which through the month average $23.6 billion a month. Year-to-date deal value (January through September) reached $212.44 billion, surpassing the nine-month totals of all previous years.
Read More